USHA NATESAN: Open Payments
NPI 1336160290 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,083 in 48 payments from 17 companies in 2025. Trend: 2023 $425 · 2024 $772 · 2025 $1,083
Food & beverage: $938Education: $145
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 8 | $248 |
| Lilly USA, LLC | 8 | $173 |
| Novo Nordisk Inc | 6 | $114 |
| Astellas Pharma US Inc | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $98 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| PFIZER INC. | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
Products named: REPATHA, TRINTELLIX, MOUNJARO, Wegovy, OTEZLA, JARDIANCE, GEMTESA, Dexcom G6 Transmitter.
Industry payments across MD — which companies pay providers there.
